ANGO Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
80.9M
-6.6%
86.6M
+10.4%
78.4M
-1.3%
79.4M
+4.9%
75.7M
Cost of Revenue
32.9M
-17.5%
39.8M
+7.8%
36.9M
+6.6%
34.6M
+2.4%
33.9M
Gross Profit
48.0M
+2.7%
46.8M
+12.8%
41.5M
-7.4%
44.8M
+7.0%
41.9M
Operating Expenses
55.3M
-2.9%
57.0M
+4.7%
54.4M
+6.9%
50.9M
-3.1%
52.5M
R&D
8.0M
-2.4%
8.2M
+15.4%
7.1M
-8.8%
7.8M
+21.1%
6.4M
SG&A
42.5M
+2.6%
41.4M
+8.5%
38.2M
+3.5%
36.9M
-9.4%
40.7M
Operating Income
-7302000
+28.4%
-10195000
+21.3%
-12951000
-111.4%
-6125000
+42.5%
-10656000
EBITDA
-1804000
+89.7%
-17513000
-1989.9%
-838000
-121.7%
-378000
+92.0%
-4706000
Net Income
-7097000
+37.8%
-11405000
-41.1%
-8084000
-27.3%
-6350000
+41.8%
-10903000
EPS (Basic)
$-0.17
+37.0%
$-0.27
-42.1%
$-0.19
-26.7%
$-0.15
+42.3%
$-0.26
EPS (Diluted)
$-0.17
+37.0%
$-0.27
-42.1%
$-0.19
-26.7%
$-0.15
+42.3%
$-0.26
Shares (Diluted)
42.0M
+0.6%
41.8M
+0.5%
41.6M
+0.1%
41.5M
+0.9%
41.2M
AngioDynamics (ANGO) โ€” Financials